Highest-materiality recent filing
Kestra Medical Q3 FY26 revenue $24.6M (+63% YoY); FY26 guidance raised to $93M
Revenue of $24.6M, up 63% YoY; gross margin expanded to 52.6% from 43.4%.
Kestra Q2 FY26 revenue $22.6M (+53% YoY); guides FY26 to $91M (+52% YoY)
Gross margin expanded to 50.6% from 39.6% YoY, driven by volume leverage and a higher mix of in-network patients.
Kestra Medical closes $148.4M public offering of 6.9M shares at $23.00
Offered 6,900,000 common shares at $23.00 per share, including full exercise of underwriters' over-allotment option of 900,000 shares.
Kestra Medical preliminary Q2 FY26 revenue up 52% YoY to $22.2-22.6M; gross margin improves to 50.0%
Revenue expected $22.2-$22.6M vs $14.7M prior year (+52% at midpoint).
Kestra's ASSURE wearable defibrillator achieves 100% conversion in largest real-world study
21,612-patient ACE-PAS trial met primary effectiveness endpoint: 100% successful conversion for VT/VF events.
Kestra Medical Q1 FY26 revenue up 52% to $19.4M; raises FY26 guidance to $88M
Revenue $19.4M (+52% YoY); gross margin expanded to 45.7% from 32.9%.
Kestra Medical Q4 rev $17.2M (+71%), FY rev $59.8M (+115%); guides FY26 $85M
Q4 revenue $17.2M (+71% YoY); FY25 revenue $59.8M (+115% YoY).
Kestra Q3 revenue $15.1M (+82% YoY); FY2025 guided $58-58.5M
Revenue $15.1M in Q3 FY2025, up 82% YoY; gross margin improved to 43.4% from 10.6%.
Issued three warrants to Kennedy Lewis Capital Partners and Perceptive Credit Holdings to purchase 434,916 common shares at $17.81 per share, exercisable until Dec 28, 2030.
On June 4, 2025, the Board of Directors (the “Board”) of Kestra Medical Technologies, Ltd. (the “Company”) elected Mr. Conor Hanley as a new member of the Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings